

ZMK 3 (25), S. 162–168  
Prof. Dr. Thomas Herdegen  
Der sichere Umgang mit Analgetika

1. Baron JA, Cole BF, Sandler RS, Haile RW, et al, A randomized trial of aspirin to prevent colorectal adenomas, *N Engl J Med* 2003, 348:891-99
2. Bolton WW, Der steinige Weg zur besser verträglichen Antirheumatika, *Dtsch Med Wochenschr* 2005, 130:1897-99
3. Bombardier C, Laine L, Reicin A, Shapiro D, et al, Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen inpatients with rheumatoid arthritis, *N Engl J Med* 2000, 343:1520-28
4. Cannon CP, Curtis SP, Fitz-Gerald GA, Krum H, et al, Cardiovascular outcomes with etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) programme: a randomised comparison, *Lancet* 2006, 368:177-91
5. Capone ML, Tacconelli S, Di Francesco L, Sacchetti A, et al, Pharmacodynamic of cyclooxygenase inhibitors in humans, *Prostaglandins Lipid Mediat* 2007, 82:85-94
6. Chan AT, Mason JE, Albert CM, Chae CU, et al, Nonsteroidal antiinflammatory drugs, acetaminophen, and the risk of cardiovascular events, *Circulation* 2006, 113:1578-87
7. Farkough ME, Kirshner H, Harrington RA, Ruland S, et al, Comparison of luniracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), cardiovascular outcomes: randomised controlled trial, *Lancet* 2004, 364:675-84
8. Fauler J, Gastrointestinale, kardiale und renale Nebenwirkungen von NSAR und Coxiben. Was ist wirklich gesichert? *MMW* 2005, 31-32: 701-5
9. Hinz B, Cheremina O, Bachmakov J, Renner B, et al, Dipyronel elicits substantial inhibition of peripheral cyclooxygenases in humans: new insights into the pharmacology of an old analgesic, *FASEB* 2007, 21: 2343-51
10. Hinz B, Cheremina O, Brune K, Acetaminophen (paracetamol) is a selective oxygenase-2-inhibitor in man, *FASEB* 2008, 22:383-90
11. Hinz B, Renner B, Brune K, Drug Insight: cyclo-oxygenase-2-inhibitors – a critical appraisal, *Nat Clin Pract Rheumatol* 2007, 3:552-60
12. Kearney PM, Baigent C, Godwin J, Halls H, et al, Do selective cyclo-oxygenase-2-inhibitors and traditional non-steroidal anti-inflammatory drugs increase the risk of atherothrombosis? Meta-analysis of randomised trials, *Brit Med J* 2006, 332:1302-8
13. Koelz HR, Beat M, Nichtsteroidale Antirheumatika, Magenschutztherapie oder COX-Hemmer? *Dt Ärzteblatt* 2004, 45:2453-58
14. Martin P-Y, Desmeules J, Unterscheidet sich die Nierentoxizität der selektiven Cyclooxygenase-2-Hemmer von jener der klassischen nicht-steroidalen Antiphlogistika? *Schweiz Med Forum* 2001, 35:868-74

15. Redaktion, Schmerzmittel bei eingeschränkter Nierenfunktion?, MMP 2007, 3:108-9
16. Takkouche B, Regueiraö-Mendez C, Etminan M, Breast cancer and use of nonsteroidal anti-inflammatory drugs: a meta-analysis, J Natl Cancer Inst 2008, 100:1439-47